ID

23791

Beschreibung

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00507689

Link

https://clinicaltrials.gov/show/NCT00507689

Stichworte

Versionen (1)
  1. 13.07.17 13.07.17 -
Hochgeladen am

13. Juli 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Chronic Hepatitis B NCT00507689

Englisch

Eligibility Chronic Hepatitis B NCT00507689

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult subjects (18-75 years of age) with either hepatitis e antigen (hbeag) positive or hbeag negative chronic hbv prior to transplant
Beschreibung

Adult | Age | Chronic Hepatitis B | Hepatitis B e antigen positive | Hepatitis B e Antigens Negative

Datentyp

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0524909
UMLS CUI [4]
C0392390
UMLS CUI [5,1]
C0019167
UMLS CUI [5,2]
C1513916
willing and able to provide written informed consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
subjects with detectable antibody to hepatitis b surface antigen performed by a local laboratory result within 30 days of screening
Beschreibung

Antibody Hepatitis B Surface Antigen Detectable Laboratory Results

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0518943
UMLS CUI [1,2]
C3830527
UMLS CUI [1,3]
C1254595
subjects must have been stable and may not have had 2 or more of the following laboratory parameters associated with decompensated liver disease: conjugated bilirubin > 1.5 x the upper limit of the normal range (uln), prothrombin time > 1.5 x uln, platelets < 60,000/mm^3, serum albumin < 3.0 g/dl
Beschreibung

Study Subject Stable status | Decompensated liver disease | Laboratory Parameters Quantity Absent | Bilirubin conjugated increased | Prothrombin time increased | Platelet Count measurement | Serum albumin measurement

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0205360
UMLS CUI [2]
C4075847
UMLS CUI [3,1]
C0022877
UMLS CUI [3,2]
C0449381
UMLS CUI [3,3]
C1265611
UMLS CUI [3,4]
C0332197
UMLS CUI [4]
C0855625
UMLS CUI [5]
C0151872
UMLS CUI [6]
C0032181
UMLS CUI [7]
C0523465
must have had at least 12 weeks of center-specific prophylactic therapy including hepatitis b immunoglobulin (hbig) posttransplant
Beschreibung

Prophylactic treatment | Hepatitis B immune globulin

Datentyp

boolean

Alias
UMLS CUI [1]
C0199176
UMLS CUI [2]
C0062525
calculated creatinine clearance ≥ 40 ml/min using the cockcroft-gault equation
Beschreibung

Estimation of creatinine clearance by Cockcroft-Gault formula

Datentyp

boolean

Alias
UMLS CUI [1]
C2711451
no significant evidence of ongoing deterioration of renal function
Beschreibung

Renal function | Deterioration Absent

Datentyp

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2,1]
C0868945
UMLS CUI [2,2]
C0332197
negative serum beta-human chorionic gonadotropin (for females of childbearing potential only)
Beschreibung

Childbearing Potential Serum pregnancy test (B-HCG) Negative

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430060
UMLS CUI [1,3]
C1513916
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with hbv recurrence, ie, confirmed hbv dna ≥ 400 copies/ml, following liver transplant
Beschreibung

Hepatitis B Recurrence | Hepatitis B DNA Measurement | Transplantation of liver Status post

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0019163
UMLS CUI [1,2]
C0034897
UMLS CUI [2]
C3641250
UMLS CUI [3,1]
C0023911
UMLS CUI [3,2]
C0231290
pregnant women, women who were breast feeding or who believed they may have wished to become pregnant during the course of the study
Beschreibung

Pregnancy | Breast Feeding | Pregnancy, Planned

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
males and females of reproductive potential who were unwilling to use an effective method of contraception during the study and for at least 30 days from the date of last dose of study drug
Beschreibung

Reproductive potential Contraceptive methods Unwilling

Datentyp

boolean

Alias
UMLS CUI [1,1]
C4034483
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080
evidence of hepatocellular carcinoma (hcc), eg, alpha-fetoprotein > 50 ng/ml, or by any other standard of care measure or presence of multifocal hcc at the time of transplantation if transplantation was within 144 weeks of screening
Beschreibung

Liver carcinoma | Alpha fetoprotein measurement | Standard of Care Measures | Liver carcinoma Multifocal | Transplantation

Datentyp

boolean

Alias
UMLS CUI [1]
C2239176
UMLS CUI [2]
C0201539
UMLS CUI [3,1]
C2936643
UMLS CUI [3,2]
C0079809
UMLS CUI [4,1]
C2239176
UMLS CUI [4,2]
C0205292
UMLS CUI [5]
C0040732
prior tdf or ftc/tdf experience post-transplant or > 12 months treatment with tdf or ftc/tdf treatment pretransplant
Beschreibung

Tenofovir disoproxil fumarate | emtricitabine

Datentyp

boolean

Alias
UMLS CUI [1]
C1099776
UMLS CUI [2]
C0909839
coinfection with hepatitis c virus (by serology), hiv, or hepatitis d virus pretransplant or at screening
Beschreibung

HCV coinfection Serology | HIV coinfection | HDV Coinfection

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1698259
UMLS CUI [1,2]
C0220911
UMLS CUI [2]
C4062778
UMLS CUI [3,1]
C0011220
UMLS CUI [3,2]
C0275524
significant renal, cardiovascular, pulmonary, or neurological disease
Beschreibung

Kidney Diseases | Cardiovascular Diseases | Lung diseases | nervous system disorder

Datentyp

boolean

Alias
UMLS CUI [1]
C0022658
UMLS CUI [2]
C0007222
UMLS CUI [3]
C0024115
UMLS CUI [4]
C0027765
known hypersensitivity to the study drugs, the metabolites, or formulation excipients
Beschreibung

Hypersensitivity Investigational New Drugs | Hypersensitivity Metabolite | Hypersensitivity Pharmaceutical Excipient

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0870883
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0015237
were likely to receive systemic drugs with nephrotoxic potential, except immunosuppressive agents (eg, cyclosporine, tacrolimus), during the course of the study
Beschreibung

Pharmaceutical Preparations Systemic | Effect Nephrotoxic | Immunosuppressive Agents | Cyclosporine | Tacrolimus

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C1280500
UMLS CUI [2,2]
C1514118
UMLS CUI [3]
C0021081
UMLS CUI [4]
C0010592
UMLS CUI [5]
C0085149
history of variceal bleeding or hepatic encephalopathy following orthotopic liver transplantation
Beschreibung

Bleeding varices | Hepatic Encephalopathy | Orthotopic liver transplant

Datentyp

boolean

Alias
UMLS CUI [1]
C0333106
UMLS CUI [2]
C0019151
UMLS CUI [3]
C0400447
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Chronic Hepatitis B NCT00507689

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age | Chronic Hepatitis B | Hepatitis B e antigen positive | Hepatitis B e Antigens Negative
Item
adult subjects (18-75 years of age) with either hepatitis e antigen (hbeag) positive or hbeag negative chronic hbv prior to transplant
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0524909 (UMLS CUI [3])
C0392390 (UMLS CUI [4])
C0019167 (UMLS CUI [5,1])
C1513916 (UMLS CUI [5,2])
Informed Consent
Item
willing and able to provide written informed consent
boolean
C0021430 (UMLS CUI [1])
Antibody Hepatitis B Surface Antigen Detectable Laboratory Results
Item
subjects with detectable antibody to hepatitis b surface antigen performed by a local laboratory result within 30 days of screening
boolean
C0518943 (UMLS CUI [1,1])
C3830527 (UMLS CUI [1,2])
C1254595 (UMLS CUI [1,3])
Study Subject Stable status | Decompensated liver disease | Laboratory Parameters Quantity Absent | Bilirubin conjugated increased | Prothrombin time increased | Platelet Count measurement | Serum albumin measurement
Item
subjects must have been stable and may not have had 2 or more of the following laboratory parameters associated with decompensated liver disease: conjugated bilirubin > 1.5 x the upper limit of the normal range (uln), prothrombin time > 1.5 x uln, platelets < 60,000/mm^3, serum albumin < 3.0 g/dl
boolean
C0681850 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C4075847 (UMLS CUI [2])
C0022877 (UMLS CUI [3,1])
C0449381 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0332197 (UMLS CUI [3,4])
C0855625 (UMLS CUI [4])
C0151872 (UMLS CUI [5])
C0032181 (UMLS CUI [6])
C0523465 (UMLS CUI [7])
Prophylactic treatment | Hepatitis B immune globulin
Item
must have had at least 12 weeks of center-specific prophylactic therapy including hepatitis b immunoglobulin (hbig) posttransplant
boolean
C0199176 (UMLS CUI [1])
C0062525 (UMLS CUI [2])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
calculated creatinine clearance ≥ 40 ml/min using the cockcroft-gault equation
boolean
C2711451 (UMLS CUI [1])
Renal function | Deterioration Absent
Item
no significant evidence of ongoing deterioration of renal function
boolean
C0232804 (UMLS CUI [1])
C0868945 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Childbearing Potential Serum pregnancy test (B-HCG) Negative
Item
negative serum beta-human chorionic gonadotropin (for females of childbearing potential only)
boolean
C3831118 (UMLS CUI [1,1])
C0430060 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Hepatitis B Recurrence | Hepatitis B DNA Measurement | Transplantation of liver Status post
Item
subjects with hbv recurrence, ie, confirmed hbv dna ≥ 400 copies/ml, following liver transplant
boolean
C0019163 (UMLS CUI [1,1])
C0034897 (UMLS CUI [1,2])
C3641250 (UMLS CUI [2])
C0023911 (UMLS CUI [3,1])
C0231290 (UMLS CUI [3,2])
Pregnancy | Breast Feeding | Pregnancy, Planned
Item
pregnant women, women who were breast feeding or who believed they may have wished to become pregnant during the course of the study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
Reproductive potential Contraceptive methods Unwilling
Item
males and females of reproductive potential who were unwilling to use an effective method of contraception during the study and for at least 30 days from the date of last dose of study drug
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
Liver carcinoma | Alpha fetoprotein measurement | Standard of Care Measures | Liver carcinoma Multifocal | Transplantation
Item
evidence of hepatocellular carcinoma (hcc), eg, alpha-fetoprotein > 50 ng/ml, or by any other standard of care measure or presence of multifocal hcc at the time of transplantation if transplantation was within 144 weeks of screening
boolean
C2239176 (UMLS CUI [1])
C0201539 (UMLS CUI [2])
C2936643 (UMLS CUI [3,1])
C0079809 (UMLS CUI [3,2])
C2239176 (UMLS CUI [4,1])
C0205292 (UMLS CUI [4,2])
C0040732 (UMLS CUI [5])
Tenofovir disoproxil fumarate | emtricitabine
Item
prior tdf or ftc/tdf experience post-transplant or > 12 months treatment with tdf or ftc/tdf treatment pretransplant
boolean
C1099776 (UMLS CUI [1])
C0909839 (UMLS CUI [2])
HCV coinfection Serology | HIV coinfection | HDV Coinfection
Item
coinfection with hepatitis c virus (by serology), hiv, or hepatitis d virus pretransplant or at screening
boolean
C1698259 (UMLS CUI [1,1])
C0220911 (UMLS CUI [1,2])
C4062778 (UMLS CUI [2])
C0011220 (UMLS CUI [3,1])
C0275524 (UMLS CUI [3,2])
Kidney Diseases | Cardiovascular Diseases | Lung diseases | nervous system disorder
Item
significant renal, cardiovascular, pulmonary, or neurological disease
boolean
C0022658 (UMLS CUI [1])
C0007222 (UMLS CUI [2])
C0024115 (UMLS CUI [3])
C0027765 (UMLS CUI [4])
Hypersensitivity Investigational New Drugs | Hypersensitivity Metabolite | Hypersensitivity Pharmaceutical Excipient
Item
known hypersensitivity to the study drugs, the metabolites, or formulation excipients
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0870883 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0015237 (UMLS CUI [3,2])
Pharmaceutical Preparations Systemic | Effect Nephrotoxic | Immunosuppressive Agents | Cyclosporine | Tacrolimus
Item
were likely to receive systemic drugs with nephrotoxic potential, except immunosuppressive agents (eg, cyclosporine, tacrolimus), during the course of the study
boolean
C0013227 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1280500 (UMLS CUI [2,1])
C1514118 (UMLS CUI [2,2])
C0021081 (UMLS CUI [3])
C0010592 (UMLS CUI [4])
C0085149 (UMLS CUI [5])
Bleeding varices | Hepatic Encephalopathy | Orthotopic liver transplant
Item
history of variceal bleeding or hepatic encephalopathy following orthotopic liver transplantation
boolean
C0333106 (UMLS CUI [1])
C0019151 (UMLS CUI [2])
C0400447 (UMLS CUI [3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video